Brexanolone

布瑞诺龙

Report date: 2025/02/06 20:00:06
NMEFirst In Class

Base Information

Drug NameBrexanolone
Drug Alias NameAllopregnanolone孕甾醇酮Allopregnalone别孕烯醇酮四氢孕酮 +[10] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGamma-aminobutyric acid A receptor modulators
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Stress Disorders, Post-TraumaticCognitive Dysfunction +[11] 
Global Approved IndicationsDepression, Postpartum
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/03/19
Country/TerritoryCanadaUnited StatesSweden +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesYale UniversityThe University Of ArizonaSupernus Pharmaceuticals Inc +[4] 
Inactive CompaniesUniversity Of Southern CaliforniaSage Therapeutics IncUniversity Of North Carolina At Chapel Hill
Active IndicationsStress Disorders, Post-TraumaticAlcoholismNeurodegenerative Diseases +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionDepression, Postpartum +[6] 

Other Information

ATC CodeN06A
Related LinksWikipediaDrugBankKEGG